Log in to save to my catalogue

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-worl...

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-worl...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7c7f88d7c9824bbc938bd6730c370b0e

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

The addition of metastasis-directed radiotherapy (MDRT) to immunotherapy in patients with advanced urothelial carcinoma (aUC) has shown promising results. We report the real-world data from the ARON-2 study (NCT05290038) on the impact of conventional (CRT) or stereotactic body radiotherapy (SBRT) on the outcome of aUC patients receiving pembrolizum...

Alternative Titles

Full title

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_7c7f88d7c9824bbc938bd6730c370b0e

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7c7f88d7c9824bbc938bd6730c370b0e

Other Identifiers

ISSN

2045-2322

E-ISSN

2045-2322

DOI

10.1038/s41598-024-70182-3

How to access this item